Joint pain treatment planning in osteoarthritis patients with chronic kidney disease

Abstract

Treatment of osteoarthritis, as the most common pathology of the musculoskeletal system, presents certain clinical difficulties in comorbid patients. The frequent combination of osteoarthritis (OA) and cardiovascular diseases (CVD), diabetes mellitus type 2 and other cardiometabolic pathologies raises questions about the safety of pain relievers in the presence of chronic kidney disease (CKD). Safe treatment for chronic pain syndrome implies an informed decision about the risks / benefits of using any analgesic intervention. Particular attention should be paid to the decision on the appointment of non-steroidal anti-inflammatory drugs (NSAIDs). An alternative strategy for the treatment of joint pain in patients with CKD may be the use of chondroitin sulfate prescription form. Particular attention should be paid to the possibility of using the parenteral form of the drug, which has reliable evidence, faster onset of the clinical effect of analgesia, with a potential protective effect on the structure of joint tissues.